✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Teva Pharmaceutical Industries Limited..

Country
Israel
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
31,173
Ticker
TEVA
Exchange
Tel
Description
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company that is predominantly engaged in the development, production, and marketing of generic medicines and specialty pharmaceuticals. I...

Teva Pharmaceutical Industries Limited..'s Financial Statements Preview

Below are the financial statements of Teva Pharmaceutical Industries Limited.., including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024 as of 2024-12-31
2023 as of 2023-12-31
Assets——
Current assets——
Cash and cash equivalents
3,300a
3,226a
Accounts receivables, net of allowance for credit losses
3,059a
3,408a
Inventories
3,007a
4,021a
Prepaid expenses
1,006a
1,255a
Other current assets
409a
504a
Assets held for sale
1,771a
70a
Total current assets
12,552a
12,485a
Deferred income taxes
1,799a
1,812a
Other non-current assets
462a
470a
Property, plant and equipment, net
4,581a
5,750a
Operating lease right-of-use assets
367a
397a
Identifiable intangible assets, net
4,418a
5,387a
Goodwill
15,147a
17,177a
Total assets
39,326a
43,479a
Liabilities and equity——
Current liabilities——
Short-term debt
1,781a
1,672a
Sales reserves and allowances
3,678a
3,535a
Accounts payables
2,203a
2,602a
Employee-related obligations
624a
611a
Accrued expenses
2,792a
2,771a
Other current liabilities
1,020a
1,044a
Liabilities held for sale
698a
13a
Total current liabilities
12,796a
12,247a
Long-term liabilities——
Deferred income taxes
483a
606a
Other taxes and long-term liabilities
4,028a
4,019a
Senior notes and loans
16,002a
18,161a
Operating lease liabilities
296a
320a
Total long-term liabilities
20,809a
23,106a
Total liabilities
33,606a
35,353a
Redeemable non-controlling interests
340a
0a
Equity——
Teva shareholders’ equity——
Ordinary shares of NIS 0.10 par value per share
58a
57a
Additional paid-in capital
27,764a
27,807a
Accumulated deficit
-15,173a
-13,534a
Accumulated other comprehensive loss
-3,148a
-2,697a
Treasury shares
-4,128a
-4,128a
Non-controlling interests
7a
620a
Total equity
5,380a
8,126a
Total liabilities, redeemable non-controlling interests and equity
39,326a
43,479a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Teva Pharmaceutical Industries Limited..’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Teva Pharmaceutical Industries Limited..'s 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?